# Evidence: absorptive dissolution testing

Parent: — · class: measurement · names merged here: absorptive dissolution; absorptive dissolution testing

3 papers measured or used it, 2 only mentioned it (of 207 kept papers). Papers in year order; each section heading ends with the paper's category / subcategory. Generated by tools/build_evidence.py from registry/concepts.csv and the cards; do not edit.

## 2017 Hate — Absorptive Dissolution Testing of Supersaturating Systems: Impact of Absorptive Sink Conditions on Solution Phase Behavior and Mass Transport · Bioperformance / Bioperformance

[2017-hate-absorptive-dissolution-supersaturating-systems](../../../cards/2017-hate-absorptive-dissolution-supersaturating-systems/paper.html) · Bioperformance / Bioperformance · measured · as: absorptive dissolution testing

| id | kind | content | locator |
|---|---|---|---|
| R7 | record, measured | donor concentration-time profiles, dissolution-absorption — suspension, powder, tablet, powder + 0.05% HPMC-AS, tablet + 0.05% HPMC-AS (P7); acid stage 0-30 min shown for the tablets only; 2 mL/min; error bars shown, n not stated — sub-table below; text: suspension donor constant at the crystalline solubility; tablet dissolved completely in the acid; after the shift the powder donor fell to the value of the suspension, the tablet donor behaved analogously, and with HPMC-AS the donor concentration fell gradually | Fig. 4a, p.19; text p.18-20 |
| R8 | record, measured | receiver concentration-time profiles, dissolution-absorption — same runs as R7 (P7); in-line UV; error bars shown, n not stated — sub-table below; text: powder and tablet Cmax "approximately 4 times higher" than that of the suspension; receiver concentration of powder and tablet then fell to a value close to the suspension value; HPMC-AS arms reached a higher Cmax | Fig. 4b, p.19; text p.20 |
| R15 | record, measured | donor concentration-time profiles of tablets in a closed compartment (D) — tablet and tablet + 0.05% HPMC-AS, pH-shift protocol without the module (P7); error bars shown, n not stated — sub-table below; acid stage: all four tablet arms ≈750-800 µg/mL at ≈1 min and ≈930-995 µg/mL from 5 to 30 min; the D-A curves plotted in Fig. 7 carry the same values as the tablet columns of R7; text: D without polymer reached the crystalline solubility at 140-160 min and D-A at 120 min (p.30); D with HPMC-AS constant over the experiment (p.24) | Fig. 7, p.24; text p.24, p.30 |
| R16 | record, measured | donor concentration with and without absorption — 500 µg/mL nevirapine, pH 6.5 phosphate buffer with 0.1% PVPVA, 4 mL/min, 120 min (P8); error bars shown, n not stated — sub-table below (donor columns); text: steeper decline with absorption than in the closed compartment | Fig. 8a, p.25; text p.24 |
| R17 | record, measured | total drug in donor plus receiver with absorption, and in solution without absorption — as R16 — sub-table below (total columns); text: total constant for 120 min with absorption; total decreasing after 60 min in the closed compartment | Fig. 8b, p.25; text p.24-25 |
| C53 | claim, generalisation, authors: "may overestimate"; "clearly seen" | Dissolution tests may overestimate the extent of supersaturation at any time point; this is clear for tablets with HPMC-AS, where the D-A donor depletes slowly while the D donor stays constant [rests on: R15, R7] | p.30 |
| C55 | claim, generalisation, authors: asserted ("overestimates") | The absorptive compartment is especially important for systems that crystallize on a slower timescale (PVPVA case): by mass balance crystallization was avoided with absorption, while the closed compartment crystallized after an hour, so the closed compartment overestimates the crystallization risk [rests on: R16, R17] | p.31 |

## 2020 Hate — Interplay of Adsorption, Supersaturation and the Presence of an Absorptive Sink on Drug Release from Mesoporous Silica-Based Formulations · Mesoporous silica / Mesoporous silica

[2020-hate-atazanavir-mesoporous-silica-adsorption-absorptive-sink-release](../../../cards/2020-hate-atazanavir-mesoporous-silica-adsorption-absorptive-sink-release/paper.html) · Mesoporous silica / Mesoporous silica · measured · as: absorptive dissolution testing

| id | kind | content | locator |
|---|---|---|---|
| R20 | record, derived (E4) for dissolution-absorption; measured for closed compartment | total drug release (%) with and without the absorptive compartment — 20% DL ATZ-MPS, dose 75 µg/mL, pH 6.8; dissolution-absorption (P9) versus closed compartment (P7), 240 min — sub-table below; text: dissolution-absorption released constantly, reaching almost 90%; closed compartment only 40%, plateau after 60 min (p.13); "plateaued at 40%" versus "90% release" (p.15) | Fig. 10c, p.11; text p.13, p.15 |
| C7 | claim, conclusion, authors: abstract: "This suggested"; results: "These observations suggest" | Depletion of drug from the donor medium by transport across the membrane promotes additional release from the silica [rests on: R20, R18] | p.1, p.13 |
| C49 | claim, recommendation, authors: "can provide"; "clearly demonstrates" | An absorptive compartment gives more in vivo relevant insight into the performance of mesoporous silica formulations than a closed-compartment test; Fig. 10c demonstrates the difference (40% versus 90%) [rests on: R20] | p.15 |

## 2020 Hate — Influence of Drug-Silica Electrostatic Interactions on Drug Release from Mesoporous Silica-Based Oral Delivery Systems · Mesoporous silica / Mesoporous silica

[2020-hate-drug-silica-electrostatic-interactions-mesoporous-release](../../../cards/2020-hate-drug-silica-electrostatic-interactions-mesoporous-release/paper.html) · Mesoporous silica / Mesoporous silica · measured · as: absorptive dissolution testing

| id | kind | content | locator |
|---|---|---|---|
| P8 | method | absorptive (dissolution-absorption) testing | p.9; Fig. 8 |
| R17 | record, measured | donor concentration (µg/mL) and total drug release (%) in absorptive dissolution — P8; KET-MPS; pH 1 for 30 min, then pH 6.8 with absorption; mean ± SD, n = 3 — sub-table below; text: abrupt donor decline on the shift, then a further gradual decline; total release increased only slightly (by 10%) over the 4 h of absorption measurement | Fig. 8a, p.19; text p.18-19 |
| R18 | record, measured | receiver concentration (µg/mL), in-line UV — P8; KET-MPS; after the shift to pH 6.8 — rises from ≈0.5 at ≈30 min to a maximum of ≈2.9 between ≈40 and ≈58 min, then falls to ≈2.0 at ≈100 min, ≈1.3 at ≈150-180 min and ≈0.63 at ≈270 min (all read from Fig. 8b); text: maximum followed by a gradual decline | Fig. 8b, p.19; text p.18 |
| C12 | claim, prior hypothesis, authors: "has been observed" | Absorptive dissolution testing alters the kinetics of competing mass-transfer processes such as crystallization or adsorption to a surface by removing drug through the membrane [rests on: cited: refs 36, 37] | p.7 |
| C22 | claim, prior hypothesis, authors: "can" | Removing drug by membrane transport can shift the drug-silica adsorption equilibrium toward desorption and improve overall release, as seen earlier for ATZ-MPS [rests on: R23; cited: ref 28] | p.18 |
| C24 | claim, conclusion, authors: "suggested" | Simultaneous absorption produced only a small amount of additional KET release (about 10% over 4 h), at least over biorelevant times, contrary to the almost complete release seen earlier for ATZ-MPS [rests on: R17, R23] | p.19 |

## Mentioned only

- 2021 Hate — [2021-hate-drug-mass-transport-supersaturated-pampa-membranes](../../../cards/2021-hate-drug-mass-transport-supersaturated-pampa-membranes/paper.html) · Bioperformance / Bioperformance (ref 14)
- 2021 Moseson — [2021-moseson-residual-crystallinity-dissolution-matrix-crystallization](../../../cards/2021-moseson-residual-crystallinity-dissolution-matrix-crystallization/paper.html) · ASD process / ASD process (ref 37)